1
|
Li J, Iwai Y, Isaacs TJ, Ma SJ, Elmore SNC, Kamran S, Oladeru OT. Palliative Care among Incarcerated Populations: A National Survey of Radiation Oncologists' Perspectives and Experiences. Int J Radiat Oncol Biol Phys 2023; 117:e36. [PMID: 37785237 DOI: 10.1016/j.ijrobp.2023.06.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Incarcerated individuals carry a high disease burden, including cancer which is now the leading cause of illness-related deaths. Disparities in access to screening, care coordination, timely treatment, and comorbidities have been identified as contributors to late-stage diagnosis and poor cancer-related outcomes. As the first of its kind, we assessed oncologists' knowledge, attitudes, and practices (KAP) in providing cancer care to incarcerated patients. MATERIALS/METHODS A KAP survey on incarcerated patients with cancer was developed and piloted with volunteer radiation oncologists. Following IRB approval, the KAP survey questionnaire included physicians' demographics and Likert scale questions on practice patterns and experiences caring for incarcerated patients. The survey was distributed to 150 medical and radiation oncologists randomly selected from national societies' membership directories (ASTRO and ASCO). Data collection took place from 7/2020-12/2021, and descriptive statistics were used for analysis. RESULTS Of the 75 surveyed radiation oncologists (RO), 34 responded with a response rate of 45% among the specialty cohort. Most RO (59%) incorrectly identified "heart disease" as the leading cause of death among incarcerated patients, followed by "substance use disorder" (19%); only 9% correctly reported "cancer" as the leading cause of death. Most RO reported caring for a patient who underwent cancer treatment while incarcerated (70%) or recently incarcerated (within 6 months of release; 63%). 38% (n = 10/26) indicated incarcerated patients presented with delayed diagnosis at consultation. 58% (n = 14/24) reported that ≥50% of their patients who were incarcerated presented with cancer-related pain, and 82% (n = 18/22) indicated that ≥50% of their patients had a history of opioid use disorder. Yet 38% (n = 9/24) reported their clinic adequately treated cancer-related pain for incarcerated patients, while 54% (n = 13/24) reported their clinic needed improvement. CONCLUSION Most radiation oncologists have experience providing cancer care for incarcerated patients and acknowledge disparities in later-stage disease presentation in this patient population. Interventions are needed to ensure cancer-related pain is appropriately managed among patients experiencing incarceration. Further studies are required to understand practice patterns and ensure equitable cancer treatment for carceral populations.
Collapse
Affiliation(s)
- J Li
- State University of New York Upstate Medical University, Syracuse, NY
| | - Y Iwai
- University of North Carolina School of Medicine, Chapel Hill, NC
| | - T J Isaacs
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL
| | - S J Ma
- Roswell Park Comprehensive Cancer Center, Buffalo, NY
| | - S N C Elmore
- Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - S Kamran
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
| | - O T Oladeru
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL
| |
Collapse
|
2
|
Ishii Y, Aiba N, Ando M, Asakura N, Bierwage A, Cara P, Dzitko H, Edao Y, Gex D, Hasegawa K, Hayashi T, Hiwatari R, Hoshino T, Ikeda Y, Ishida S, Isobe K, Iwai Y, Jokinen A, Kasugai A, Kawamura Y, Kim JH, Kondo K, Kwon S, Lorenzo SC, Masuda K, Matsuyama A, Miyato N, Morishita K, Nakajima M, Nakajima N, Nakamichi M, Nozawa T, Ochiai K, Ohta M, Oyaidzu M, Ozeki T, Sakamoto K, Sakamoto Y, Sato S, Seto H, Shiroto T, Someya Y, Sugimoto M, Tanigawa H, Tokunaga S, Utoh H, Wang W, Watanabe Y, Yagi M. R&D Activities for Fusion DEMO in the QST Rokkasho Fusion Institute. Fusion Science and Technology 2021. [DOI: 10.1080/15361055.2021.1925030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Y. Ishii
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Aiba
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - M. Ando
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Asakura
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - A. Bierwage
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - P. Cara
- IFMIF/EVEDA Project Team, Rokkasho-Vill., Japan
| | - H. Dzitko
- Fusion for Energy, Broader Approach, Garching, Germany
| | | | - D. Gex
- Fusion for Energy, Broader Approach, Garching, Germany
| | - K. Hasegawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Hayashi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - R. Hiwatari
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Hoshino
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Ikeda
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Ishida
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Isobe
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Iwai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - A. Jokinen
- IFMIF/EVEDA Project Team, Rokkasho-Vill., Japan
| | - A. Kasugai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Kawamura
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - J. H. Kim
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Kondo
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Kwon
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. C. Lorenzo
- Fusion for Energy, Broader Approach, Barcelona, Spain
| | - K. Masuda
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - A. Matsuyama
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Miyato
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Morishita
- Kyoto University, Institute of Advanced Energy, Uji, Japan
| | - M. Nakajima
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Nakajima
- National Institute for Fusion Science, Department of Helical Plasma Research Rokkasho Research Center, Rokkasho-Vill., Japan
| | - M. Nakamichi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Nozawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Ochiai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Ohta
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Oyaidzu
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Ozeki
- NAT Corporation, Tohoku Branch Office, Rokkasho-Vill., Japan
| | - K. Sakamoto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Sakamoto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Sato
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - H. Seto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Shiroto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Someya
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Sugimoto
- NAT Corporation, Tohoku Branch Office, Rokkasho-Vill., Japan
| | - H. Tanigawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Tokunaga
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - H. Utoh
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - W. Wang
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Watanabe
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Yagi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| |
Collapse
|
3
|
Saito M, Iwai Y, Kurokawa M, Harada R, Nemoto MW, Uno T. The Relationship Between Pelvic Fractures Within the Irradiation Field Among Elderly Asian Women Who Have Received Definitive Radiation Therapy for Cervical Cancer Treatment. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Fujimoto A, Iwai Y, Muramatsu S, Ishikawa T, Shinkuma S, Abe R. 493 A deep neural network for the early image diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
5
|
Katsumi T, Hama N, Iwai Y, Kimura K, Ansai O, Suzuki T, Abe R. Mycoplasma pneumoniae-associated Stevens-Johnson syndrome: characteristic histological features of mucosal lesion. J Eur Acad Dermatol Venereol 2020; 35:e56-e57. [PMID: 32594552 DOI: 10.1111/jdv.16796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Accepted: 06/22/2020] [Indexed: 11/29/2022]
Affiliation(s)
- T Katsumi
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - N Hama
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - Y Iwai
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - K Kimura
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - O Ansai
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - T Suzuki
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - R Abe
- Division of Dermatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| |
Collapse
|
6
|
Izumi K, Suzuki K, Hashimoto M, Endoh T, Doi K, Iwai Y, Kaneko Y, Jinzaki M, Ko S, Takeuchi T. AB1103 AUTOMATIC FINGER JOINT BONE EROSION SCORE PREDICTION CONSIDERING 2-TIME-POINT X-RAYS OF PATIENTS WITH RHEUMATOID ARTHRITIS BY DEEP LEARNING. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Medical image analysis using deep learning (DL) has been attracting attention. In previous research, we proposed a DL method for detection of joint region and evaluation for bone destruction at a single point in time in hand X-rays of patients with rheumatoid arthritis (RA) [1-2]. However, in the score of van der Heijde-modified total Sharp scores (mTSS) in X-rays, it is difficult to apply the method as it is. In mTSS, score difference between 2-time points is important, and there is a problem that the score at each time varies depending on the doctor who evaluates.Objectives:We aimed at developing an mTSS scoring method considering 2-time-point difference with a DL method.Methods:A total of 104 X-ray image sets of both hands at two time points with an interval of ≥1 year were randomly obtained from patients with RA who had visited our clinic in 2015. Well-trained doctors determined the erosion scores of MP and PIP/IP joints of each hand in X-rays according to mTSS. These evaluations of hand joints were performed using our developed annotation software tool. In the learning phase, joint images were randomly divided into five sets for 5-fold cross-validation. We utilized a convolutional neural network model, such as SSD [3], for detecting joint regions and classifying the scores (Fig 1).Figure1.The models for classification were designed in consideration of the difference in erosion scores of each patient between the 2-time points of X-rays. The loss function of the DL model was defined bellow;SCE: softmax cross entropyMSE: mean squared errort: training datay: output of DL model0: the former time point1: the latter time pointT: transpose of matrixHere, the coefficient γ is designed to reduce the error for another set of scores with equal differences. The first term of the loss function works to optimize the score at each time point, and the second term works to optimize the score difference at both time points. Thus, our method can be trained without being affected by characteristic training data.Results:The number of joints with differences in erosion score between the former and latter time points was 1 (-2 points), 9 (-1), 2015 (0), 32 (+1), 17 (+2), and 6 (+3). There were no joints with score changes of -5, -4, -3, +4, and +5 points.As a performance of predicting the difference in erosion score between the 2-time points of each patient’s X-ray, our models presented a mean error of 0.412 per each joint in one set for 5-cross validation as compared with physicians’ evaluation (Fig 2).Figure 2.Conclusion:Our DL-based models to predict hand joint erosion scores in X-rays were developed with relatively small samples. This suggests that the predictive performance may increase by collecting more training dataset. Next, we will apply our method to the prediction of joint space narrowing score.References:[1]Izumi K, Hashimoto M, Suzuki K, et al. Detecting Hand Joint Ankylosis in Radiographic Images Using Deep Learning: A Step in Developing Automatic Radiographic Scoring System for Bone Destruction.Arthritis Rheumatol2018;70 (suppl 10).[2]Izumi K, Suzuki K, Hashimoto M, et al. SAT0543 AUTOMATIC DETECTION OF HAND JOINT REGION, ANKYLOSIS AND SUBLUXATION IN RADIOGRAPHIC IMAGES USING DEEP LEARNING: DEVELOPMENT OF ARTIFICIAL INTELLIGENCE-BASED RADIOGRAPHIC EVALUATION SYSTEM FOR BONE DESTRUCTION.Annals of the Rheumatic Diseases2019;78 (suppl 2), pp. 1364-1364.[3]Liu W, Anguelov D, Szgedy C, et al. SSD: single shot multibox detector.European Conference on Computer Vision (ECCV) 2016.Acknowledgments:Izumi and Suzuki are contributed equally.Disclosure of Interests:Keisuke Izumi Grant/research support from: Asahi Kasei Pharma, Takeda Pharmaceutical Co., Ltd., Speakers bureau: Asahi Kasei Pharma Corp, Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., Kanata Suzuki Employee of: Fujitsu Laboratories Ltd., Masahiro Hashimoto: None declared, Toshio Endoh Employee of: Fujitsu Laboratories Ltd., Kentaro Doi Employee of: Fujitsu Ltd., Yuki Iwai Employee of: Fujitsu Ltd., Yuko Kaneko Speakers bureau: AbbVie, Eisai Pharmaceutical, Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb, Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Santen Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd. and UCB Japan Co. Ltd., Masahiro Jinzaki: None declared, Shigeru Ko Grant/research support from: Fujitsu Ltd., Tsutomu Takeuchi Grant/research support from: Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Eisai Co., Ltd., AYUMI Pharmaceutical Corporation, Nipponkayaku Co. Ltd., Novartis Pharma K.K., Teijin, Consultant of: Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Abbivie GK, Nipponkayaku Co.Ltd, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., UCB Japan Co. Ltd., Speakers bureau: Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., Celltrion Inc., Nipponkayaku Co. Ltd., and UCB Japan
Collapse
|
7
|
Nemoto MW, Iwai Y, Kanazawa A, Kurokawa M, Saito M, Harada R, Kobayashi H, Uno T. Single-Institution Experience in 3D MRI/CT-Based Brachytherapy for Cervical Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1747] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Koyama N, Watanabe Y, Iwai Y, Miwa C, Nagai Y, Aoshiba K, Nakamura H. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion. Neoplasma 2019; 65:132-139. [PMID: 29322797 DOI: 10.4149/neo_2018_170206n78] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Malignant pleural effusion (MPE) is a common complication occurring in cancer patients, and its management affects the prognosis of these patients. Preclinical and clinical studies have reported that treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin (CBDCA) is effective against intraperitoneal malignant tumors. To investigate the effectiveness of nab-paclitaxel plus CBDCA therapy for MPEs arising in patients with non-small cell lung cancer (NSCLC), we retrospectively analyzed the clinicopathological characteristics of 40 patients with stage IIIb or IV NSCLC who were treated with nab-paclitaxel plus CBDCA from 2013 to 2016. Out of 26 patients with MPEs who were treated with nab-paclitaxel plus CBDCA in this study, 21 patients (80.8%) had effective responses in MPEs; 6 of 21 patients exhibited complete responses (23.1%) and 15 of 21 had partial responses (57.7%). Kaplan-Meier survival curves and log-rank tests to evaluate the effectiveness of nab-paclitaxel plus CBDCA therapy against MPEs showed longer median progression-free survival (323 days vs. 26 days; p=0.009) and overall survival (not reached vs. 199 days; p=0.047) in patients with complete responses compared with those who achieved no response. There were no statistical differences between therapeutic effects on MPEs and those on systemic lesions. Nab-paclitaxel plus CBDCA therapy may be a preferred therapeutic option for patients with NSCLC who experience MPEs, and its effectiveness in treatment of MPEs may need to be evaluated separately from its therapeutic responses in systemic lesions.
Collapse
|
9
|
Uno T, Kobayashi H, Watanabe-Nemoto M, Harada R, Saito M, Kanazawa A, Iwai Y, Murakami K, Matsubara H. EP-1401 Practice-based clinical outcome of definitive radiation therapy for superficial esophageal cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31821-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Saleem M, Yoshinari N, Nakamura S, Sumi Y, Iwai Y, Ozaki Y, Masuda Y, Uchida K, Taguchi A. Improvement of salivary flow and oral wetness by a lip trainer device and sonic toothbrush in older Japanese men and women with dry mouth. J Oral Sci 2019; 61:221-228. [DOI: 10.2334/josnusd.18-0012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Murtaza Saleem
- Department Oral Health Promotion, Graduate School of Oral Medicine, Matsumoto Dental University
| | - Nobuo Yoshinari
- Department Oral Health Promotion, Graduate School of Oral Medicine, Matsumoto Dental University
- Department of Operative Dentistry, Endodontology and Periodontology, School of Dentistry, Matsumoto Dental University
| | - Suguru Nakamura
- Department of Operative Dentistry, Endodontology and Periodontology, School of Dentistry, Matsumoto Dental University
| | - Yasunori Sumi
- Department of Center for Development of Advanced Medicine for Dental Diseases, National Center for Geriatrics and Gerontology
| | - Yukiko Iwai
- Department of Operative Dentistry, Endodontology and Periodontology, School of Dentistry, Matsumoto Dental University
| | - Yuki Ozaki
- Department of Operative Dentistry, Endodontology and Periodontology, School of Dentistry, Matsumoto Dental University
| | - Yuji Masuda
- Division of Oral and Maxillofacial Biology, Institute for Oral Science, Matsumoto Dental University
| | - Keiichi Uchida
- Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University
| | - Akira Taguchi
- Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University
| |
Collapse
|
11
|
Kanai K, Yokota T, Shibuya K, Nakazato T, Kanouchi T, Iwai Y, Oyama G, Shimo Y, Shimizu T, Hattori N, Kuwabara S. Increased motor axonal persistent sodium currents is associated with rapid regional spreading in amyotrophic lateral sclerosis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3779] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Shu WM, Kawakubo Y, O’hira S, Oya Y, Hayashi T, Nakamura H, Iwai Y, Nishi MF, Gentile CA, Skinner CH, Langish S, Guttadora G, Carpe A, Young KM. Tritium Decontamination of TFTR D-T Plasma Facing Components Using an Ultra Violet Laser. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a22675] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- W. M. Shu
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - Y. Kawakubo
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - S. O’hira
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - Y. Oya
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - T. Hayashi
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - H. Nakamura
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - Y. Iwai
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - M. F. Nishi
- Japan Atomic Energy Research Institute, Tokai, Ibaraki 319-1195, Japan
| | - C. A. Gentile
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| | - C. H. Skinner
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| | - S. Langish
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| | - G. Guttadora
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| | - A. Carpe
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| | - K. M. Young
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543, USA
| |
Collapse
|
13
|
Iwai Y, Misaki Y, Hayashi T, Yamanishi T, Konishi S, Nishi M, Ninomiya R, Yanagimachi S, Senrui S, Yoshida H. The Water Detritiation System of the ITER Tritium Plant. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a22759] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Iwai
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - Y. Misaki
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - T. Hayashi
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - T. Yamanishi
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - S. Konishi
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - M. Nishi
- Tritium Engineering Laboratory Japan Atomic Energy Research Institute Tokai, Ibaraki 319-1195, Japan +81-29282-6393
| | - R. Ninomiya
- Showa Engineering Co., LTD Minato-ku, Tokyo 108-0023, Japan +81-33457-5010
| | - S. Yanagimachi
- Showa Engineering Co., LTD Minato-ku, Tokyo 108-0023, Japan +81-33457-5010
| | - S. Senrui
- Showa Engineering Co., LTD Minato-ku, Tokyo 108-0023, Japan +81-33457-5010
| | - H. Yoshida
- ITER-JCT Naka, Ibaraki, 311-0102, Japan +81-29270-7710
| |
Collapse
|
14
|
Kobayashi K, Hayashi T, Iwai Y, Asanuma N, Nishi M. Tritium Behavior Study for Detritiation of Atmosphere in a Room. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a22672] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Kobayashi
- Tritium Engineering Laboratory, Dept. of Fusion Engineering Research, Japan Atomic Energy Research Institute Tokai-mura, Naka-gun,Ibaraki-ken 319-1195, Japan +81-29-282-6207
| | - T. Hayashi
- Tritium Engineering Laboratory, Dept. of Fusion Engineering Research, Japan Atomic Energy Research Institute Tokai-mura, Naka-gun,Ibaraki-ken 319-1195, Japan +81-29-282-6207
| | - Y. Iwai
- Tritium Engineering Laboratory, Dept. of Fusion Engineering Research, Japan Atomic Energy Research Institute Tokai-mura, Naka-gun,Ibaraki-ken 319-1195, Japan +81-29-282-6207
| | - N. Asanuma
- Tritium Engineering Laboratory, Dept. of Fusion Engineering Research, Japan Atomic Energy Research Institute Tokai-mura, Naka-gun,Ibaraki-ken 319-1195, Japan +81-29-282-6207
| | - M. Nishi
- Tritium Engineering Laboratory, Dept. of Fusion Engineering Research, Japan Atomic Energy Research Institute Tokai-mura, Naka-gun,Ibaraki-ken 319-1195, Japan +81-29-282-6207
| |
Collapse
|
15
|
Hayashi T, Isobe K, Kobayashi K, Iwai Y, Kawamura Y, Nakamura H, Shu WM, Arita T, Hoshi S, Suzuki T, Yamada M, Yamanishi T. Recent Activities on Tritium Technologies for ITER and Fusion Reactors at JAEA. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Hayashi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - K. Isobe
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - K. Kobayashi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - Y. Iwai
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - Y. Kawamura
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - H. Nakamura
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - W. M. Shu
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - T. Arita
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - S. Hoshi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - T. Suzuki
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - M. Yamada
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - T. Yamanishi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Toka-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| |
Collapse
|
16
|
Cristescu IR, Travis J, Iwai Y, Kobayashi K, Murdoch D. Simulation of Tritium Spreading in Controlled Areas after a Tritium Release. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a966] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Ioana-R. Cristescu
- Forschungszentrum Karlsruhe Tritium Laboratory, IKET. P.O.Box 3640, D-76021 Karlsruhe, Germany
| | - J. Travis
- Tritium Laboratory, IKET. P.O.Box 3640, D-76021 Karlsruhe, Germany
| | - Y. Iwai
- JAERI, Tokai, Ibaraki, 319-1195 Japan
| | | | - D. Murdoch
- EFDA Close Support Unit, Boltzmannstrasse 2, D-85748, Garching bei Munchen, Germany
| |
Collapse
|
17
|
Hayashi T, Kobayashi K, Iwai Y, Isobe K, Nakamura H, Kawamura Y, Shu W, Suzuki T, Yamada M, Yamanishi T. Tritium Safety Study Using Caisson Assembly (CATS) at TPL/JAEA. Fusion Science and Technology 2017. [DOI: 10.13182/fst08-a1822] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Hayashi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - K. Kobayashi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - Y. Iwai
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - K. Isobe
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - H. Nakamura
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - Y Kawamura
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - W. Shu
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - T. Suzuki
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - M. Yamada
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| | - T. Yamanishi
- Tritium Technology Group, Directorates of Fusion Energy Research, Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki pref., 319-1195 JAPAN
| |
Collapse
|
18
|
Monai H, Ohkura M, Tanaka M, Oe Y, Konno A, Hirai H, Mikoshiba K, Itohara S, Nakai J, Iwai Y, Hirase H. P306 Calcium imaging reveals glial involvement in transcranial direct current stimulation-induced plasticity in mouse brain. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2016.10.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Iwai Y, Koyama N, Watanabe Y, Miwa C, Nagai Y, Koyama S. 472P Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Iwai Y, Koyama N, Watanabe Y, Miwa C, Nagai Y, Koyama S. 472P Effectiveness of nab-paclitaxel for malignant effusion in nonsmall cell lung cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00630-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
21
|
Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, Nomura F, Shibuya K, Sekiguchi Y, Iwai Y, Watanabe K, Amino H, Ohwada C, Takeuchi M, Sakaida E, Nakaseko C, Kuwabara S. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open 2015; 5:e009157. [PMID: 26560063 PMCID: PMC4654348 DOI: 10.1136/bmjopen-2015-009157] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVE POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) syndrome is a rare multisystem disease characterised by plasma cell dyscrasia and overproduction of vascular endothelial growth factor (VEGF). VEGF is assumed to be useful in monitoring disease activity, because VEGF levels usually decrease after treatment. However, there is no study to investigate whether the extent of decrease in VEGF correlates with clinical outcome. We tested the predictive efficacy of serum VEGF levels in POEMS syndrome. METHOD This was an institutional review board approved retrospective observational cohort study of 20 patients with POEMS monitored regularly for more than 12 months (median follow-up, 87 months) after treatment onset using our prospectively accumulated database of POEMS from 1999 to 2015. Patients were treated by autologous peripheral blood stem cell transplantation or thalidomide administration. Serum VEGF was measured by ELISA. Outcome measures included clinical and laboratory findings and relapse-free survival. RESULTS Serum VEGF levels decreased rapidly after treatment, and stabilised by 6 months post treatment. Patients with normalised serum VEGF levels (<1040 pg/mL) at 6 months showed prolonged relapse-free survival (HR=12.81, 95% CI 2.691 to 90.96; p=0.0001) and greater later clinical improvement. The rate of serum VEGF reduction over the first 6 months post treatment correlated with increased grip strength, serum albumin levels, and compound muscle action potential amplitudes at 12 months. CONCLUSIONS Serum VEGF level at 6 months post treatment is a predicative biomarker for disease activity and prognosis in POEMS syndrome. Serum VEGF could be used as a surrogate endpoint for relapse-free survival or clinical or laboratory improvement of POEMS syndrome for clinical trials.
Collapse
Affiliation(s)
- S Misawa
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Sato
- Clinical Research Center, Chiba University Hospital, Chiba, Japan
| | - K Katayama
- Clinical Research Center, Chiba University Hospital, Chiba, Japan
| | - H Hanaoka
- Clinical Research Center, Chiba University Hospital, Chiba, Japan
| | - S Sawai
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - M Beppu
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - F Nomura
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - K Shibuya
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Sekiguchi
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Iwai
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - K Watanabe
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - H Amino
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - C Ohwada
- Department of Hematology, Chiba University Hospital, Chiba, Japan
| | - M Takeuchi
- Department of Hematology, Chiba University Hospital, Chiba, Japan
| | - E Sakaida
- Department of Hematology, Chiba University Hospital, Chiba, Japan
| | - C Nakaseko
- Department of Hematology, Chiba University Hospital, Chiba, Japan
| | - S Kuwabara
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| |
Collapse
|
22
|
Nomoto A, Sakumi A, Takahashi W, Igaki H, Iwai Y, Yoda K, Nakagawa K. PD-0451: Plan comparison of volumetric modulated arc therapy with gamma knife radiosurgery for multiple brain metastases. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40447-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Sakumi A, Yamamoto K, Haga A, Okuma K, Igaki H, Iwai Y, Yoda K, Nakagawa K. Impact of a Low Transmission Multileaf Collimator on the Parotid Grand Dose in Head and Neck Volumetric Modulated Arc Therapy Planning: A Dose-Volume Histogram Comparison Between 2-Step Adaptive and Simultaneously Integrated Boost Techniques. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Kanai K, Yokota T, Shibuya K, Kanouchi T, Iwai Y, Misawa S, Oyama G, Shimo Y, Fujimaki M, Kagamihara Y, Shimizu T, Hattori N, Kuwabara S. P856: The effects of motor axonal potassium currents on the disease progression of amyotrophic lateral sclerosis. Clin Neurophysiol 2014. [DOI: 10.1016/s1388-2457(14)50886-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Uchida Y, Iwai Y, Akita T, Mitome T, Suzuki K, Tamura R, Nishiyama N. Magnetically transportable core–shell emulsion droplets with an antioxidative all-organic paramagnetic liquid shell. J Mater Chem B 2014; 2:4130-4133. [DOI: 10.1039/c4tb00546e] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Nitroxide radical liquid microcapsules as an all-organic flexible antioxidative magnetic carrier for nanoliter cargoes have been successfully fabricated.
Collapse
Affiliation(s)
- Y. Uchida
- Graduate School of Engineering Science
- Osaka University
- Toyonaka, Japan
- Japan Science and Technology Agency
- Saitama 332-0012, Japan
| | - Y. Iwai
- Graduate School of Engineering Science
- Osaka University
- Toyonaka, Japan
| | - T. Akita
- Graduate School of Engineering Science
- Osaka University
- Toyonaka, Japan
| | - T. Mitome
- Graduate School of Engineering Science
- Osaka University
- Toyonaka, Japan
| | - K. Suzuki
- Graduate School of Environmental and Human Studies
- Kyoto University
- Kyoto 606-8501, Japan
| | - R. Tamura
- Graduate School of Environmental and Human Studies
- Kyoto University
- Kyoto 606-8501, Japan
| | - N. Nishiyama
- Graduate School of Engineering Science
- Osaka University
- Toyonaka, Japan
| |
Collapse
|
26
|
Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, Nagai J, Jona M, Tokuhara Y, Ohkawa R, Albers HM, Ovaa H, Aoki J, Chun J, Yatomi Y, Ueda H, Miyasaka M, Miyasaka N, Nanki T. THU0106 Lysophosphatidic Acid Receptor LPA1 is Essential for Development of Arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Sakumi A, Mizuno K, Nishijima Y, Uesaka M, Haga A, Iwai Y, Yoda K, Nakagawa K. PO-0873: Evaluation of an intrafraction 4D cone-beam CT (CBCT) imaging system. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33179-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Hayami S, Tsunoda T, Field HI, Matsuda K, Neal DE, Ponder BAJ, Maehara Y, Nakamura Y, Hamamoto R. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 2013; 52:126-39. [PMID: 23011637 DOI: 10.1002/gcc.22012] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Accepted: 08/20/2012] [Indexed: 01/11/2023] Open
Abstract
Histone lysine methylation plays a fundamental role in chromatin organization. Although a set of histone methyltransferases have been identified and biochemically characterized, the pathological roles of their dysfunction in human cancers are still not well understood. In this study, we demonstrate important roles of WHSC1L1 in human carcinogenesis. Expression levels of WHSC1L1 transcript were significantly elevated in various human cancers including bladder carcinoma. Immunohistochemical analysis of bladder, lung, and liver cancers confirmed overexpression of WHSC1L1. WHSC1L1-specific small interfering RNAs significantly knocked down its expression and resulted in suppression of proliferation of bladder and lung cancer cell lines. WHSC1L1 knockdown induced cell cycle arrest at the G(2)/M phase followed by multinucleation of cancer cells. Expression profile analysis using Affymetrix GeneChip(®) showed that WHSC1L1 affected the expression of a number of genes including CCNG1 and NEK7, which are known to play crucial roles in the cell cycle progression at mitosis. As WHSC1L1 expression is significantly low in various normal tissues including vital organs, WHSC1L1 could be a good candidate molecule for development of novel treatment for various types of cancer.
Collapse
Affiliation(s)
- Daechun Kang
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Unoki M, Masuda A, Dohmae N, Arita K, Yoshimatsu M, Iwai Y, Fukui Y, Ueda K, Hamamoto R, Shirakawa M, Sasaki H, Nakamura Y. Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6). J Biol Chem 2013; 288:6053-62. [PMID: 23303181 DOI: 10.1074/jbc.m112.433284] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
JMJD6 is reported to hydroxylate lysyl residues of a splicing factor, U2AF65. In this study, we found that JMJD6 hydroxylates histone lysyl residues. In vitro experiments showed that JMJD6 has a binding affinity to histone proteins and hydroxylates multiple lysyl residues of histone H3 and H4 tails. Using JMJD6 knock-out mouse embryos, we revealed that JMJD6 hydroxylates lysyl residues of histones H2A/H2B and H3/H4 in vivo by amino acid composition analysis. 5-Hydroxylysine was detected at the highest level in histones purified from murine testis, which expressed JMJD6 at a significantly high level among various tissues examined, and JMJD6 overexpression increased the amount of 5-hydroxylysine in histones in human embryonic kidney 293 cells. These results indicate that histones are additional substrates of JMJD6 in vivo. Because 5-hydroxylation of lysyl residues inhibited N-acetylation and N-methylation by an acetyltransferase and a methyltransferase, respectively, in vitro, histone 5-hydroxylation may have important roles in epigenetic regulation of gene transcription or chromosomal rearrangement.
Collapse
Affiliation(s)
- Motoko Unoki
- Division of Epigenetics, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, Dohmae N, Field HI, Tsunoda T, Kobayashi T, Akasu T, Sugiyama M, Ohnuma SI, Atomi Y, Ponder BAJ, Nakamura Y, Hamamoto R. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res 2012; 72:3217-27. [PMID: 22556262 DOI: 10.1158/0008-5472.can-11-3701] [Citation(s) in RCA: 139] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Although the physiologic significance of lysine methylation of histones is well known, whether lysine methylation plays a role in the regulation of nonhistone proteins has not yet been examined. The histone lysine methyltransferase SETD8 is overexpressed in various types of cancer and seems to play a crucial role in S-phase progression. Here, we show that SETD8 regulates the function of proliferating cell nuclear antigen (PCNA) protein through lysine methylation. We found that SETD8 methylated PCNA on lysine 248, and either depletion of SETD8 or substitution of lysine 248 destabilized PCNA expression. Mechanistically, lysine methylation significantly enhanced the interaction between PCNA and the flap endonuclease FEN1. Loss of PCNA methylation retarded the maturation of Okazaki fragments, slowed DNA replication, and induced DNA damage, and cells expressing a methylation-inactive PCNA mutant were more susceptible to DNA damage. An increase of methylated PCNA was found in cancer cells, and the expression levels of SETD8 and PCNA were correlated in cancer tissue samples. Together, our findings reveal a function for lysine methylation on a nonhistone protein and suggest that aberrant lysine methylation of PCNA may play a role in human carcinogenesis.
Collapse
Affiliation(s)
- Masashi Takawa
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, and National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Yoshimura M, Iwai Y. A Case of Sphenoorbital Meningioma with Difficulty to Predict the Visual Function during Surgical Procedure by Using VEP. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Iwai Y, Yamanaka K, Yoshimura M. Gamma Knife Radiosurgery for Skull Base Meningiomas: Long-Term Results of Low-Dose Treatment. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Iwai Y, Yamanaka K, Yoshimura M. Long-Term Results of Partial Removal and Boost Gamma Knife Radiosurgery for Large Vestibular Schwannomas. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
34
|
Sakumi A, Haga A, Shiraishi K, Onoe T, Yamamoto K, Nomoto A, Iwai Y, Yoda K, Ohtomo K, Nakagawa K. EP-1532 INTERCOMPARISON OF IMPACT OF CONTINUOUSLY VARIABLE DOSE RATE ON THREE TREATMENT PLANNING SYSTEMS FOR ELEKTA VMAT. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71865-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
35
|
Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Shimizu N, Tanaka H, Tsunoda T, Field HI, Kelly JD, Neal DE, Ponder BAJ, Maehara Y, Nakamura Y, Hamamoto R. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila) 2011; 4:2051-61. [PMID: 21930796 DOI: 10.1158/1940-6207.capr-11-0290] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Histone methyltransferases and demethylases are known to regulate transcription by altering the epigenetic marks on histones, but the pathologic roles of their dysfunction in human diseases, such as cancer, still remain to be elucidated. Herein, we show that the histone demethylase JMJD2B is involved in human carcinogenesis. Quantitative real-time PCR showed notably elevated levels of JMJD2B expression in bladder cancers, compared with corresponding nonneoplastic tissues (P < 0.0001), and elevated protein expression was confirmed by immunohistochemistry. In addition, cDNA microarray analysis revealed transactivation of JMJD2B in lung cancer, and immunohistochemical analysis showed protein overexpression in lung cancer. siRNA-mediated reduction of expression of JMJD2B in bladder and lung cancer cell lines significantly suppressed the proliferation of cancer cells, and suppressing JMJD2B expression lead to a decreased population of cancer cells in S phase, with a concomitant increase of cells in G(1) phase. Furthermore, a clonogenicity assay showed that the demethylase activity of JMJD2B possesses an oncogenic activity. Microarray analysis after knockdown of JMJD2B revealed that JMJD2B could regulate multiple pathways which contribute to carcinogenesis, including the cell-cycle pathway. Of the downstream genes, chromatin immunoprecipitation showed that CDK6 (cyclin-dependent kinase 6), essential in G(1)-S transition, was directly regulated by JMJD2B, via demethylation of histone H3-K9 in its promoter region. Expression levels of JMJD2B and CDK6 were significantly correlated in various types of cell lines. Deregulation of histone demethylation resulting in perturbation of the cell cycle, represents a novel mechanism for human carcinogenesis and JMJD2B is a feasible molecular target for anticancer therapy.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Yamanishi T, Hayashi T, Iwai Y, Isobe K, Hara M, Sugiyama T, Okuno K. Recent activities of R&D on effects of tritium water on confinement materials and tritiated water processing. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2011.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BAJ, Nakamura Y, Hamamoto R. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 2011; 13:887-98. [PMID: 22028615 PMCID: PMC3201566 DOI: 10.1593/neo.11048] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Revised: 09/01/2011] [Accepted: 09/06/2011] [Indexed: 11/18/2022]
Abstract
A number of histone methyltransferases have been identified and biochemically characterized, but the pathologic roles of their dysfunction in human diseases like cancer are not well understood. Here, we demonstrate that Wolf-Hirschhorn syndrome candidate 1 (WHSC1) plays important roles in human carcinogenesis. Transcriptional levels of this gene are significantly elevated in various types of cancer including bladder and lung cancers. Immunohistochemical analysis using a number of clinical tissues confirmed significant up-regulation of WHSC1 expression in bladder and lung cancer cells at the protein level. Treatment of cancer cell lines with small interfering RNA targeting WHSC1 significantly knocked down its expression and resulted in the suppression of proliferation. Cell cycle analysis by flow cytometry indicated that knockdown of WHSC1 decreased the cell population of cancer cells at the S phase while increasing that at the G(2)/M phase. WHSC1 interacts with some proteins related to the WNT pathway including β-catenin and transcriptionally regulates CCND1, the target gene of the β-catenin/Tcf-4 complex, through histone H3 at lysine 36 trimethylation. This is a novel mechanism for WNT pathway dysregulation in human carcinogenesis, mediated by the epigenetic regulation of histone H3. Because expression levels of WHSC1 are significantly low in most normal tissue types, it should be feasible to develop specific and selective inhibitors targeting the enzyme as antitumor agents that have a minimal risk of adverse reaction.
Collapse
Affiliation(s)
- Gouji Toyokawa
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Department of Surgery and Science, Graduate School of Medical Science, Kyusyu University, Fukuoka, Japan
| | - Hyun-Soo Cho
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Ken Masuda
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yuka Yamane
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Masanori Yoshimatsu
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Department of Surgery and Science, Graduate School of Medical Science, Kyusyu University, Fukuoka, Japan
| | - Shinya Hayami
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Masashi Takawa
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yukiko Iwai
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yataro Daigo
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Department of Medical Oncology, Shiga University of Medical Science, Seta Tsukinowa-cho, Shiga, Japan
| | - Eiju Tsuchiya
- Department of Pathology, Saitama Cancer Center, Saitama, Japan
- Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan
| | | | - Helen I Field
- Department of Genetics, University of Cambridge, Cambridge, UK
| | - John D Kelly
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Cambridge, UK
- Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK
| | - David E Neal
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Cambridge, UK
| | - Yoshihiko Maehara
- Department of Surgery and Science, Graduate School of Medical Science, Kyusyu University, Fukuoka, Japan
| | - Bruce AJ Ponder
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Cambridge, UK
| | - Yusuke Nakamura
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Ryuji Hamamoto
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Cambridge, UK
| |
Collapse
|
38
|
|
39
|
Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder BAJ, Nakamura Y, Hamamoto R. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011; 102:1298-305. [PMID: 21539681 DOI: 10.1111/j.1349-7006.2011.01958.x] [Citation(s) in RCA: 154] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The emphasis in anticancer drug discovery has always been on finding a drug with great antitumor potential but few side-effects. This can be achieved if the drug is specific for a molecular site found only in tumor cells. Here, we find the enhancer of zeste homolog 2 (EZH2) to be highly overexpressed in lung and other cancers, and show that EZH2 is integral to proliferation in cancer cells. Quantitative real-time PCR analysis revealed higher expression of EZH2 in clinical bladder cancer tissues than in corresponding non-neoplastic tissues (P < 0.0001), and we confirmed that a wide range of cancers also overexpress EZH2, using cDNA microarray analysis. Immunohistochemical analysis showed positive staining for EZH2 in 14 of 29 cases of bladder cancer, 135 of 292 cases of non-small-cell lung cancer (NSCLC), and 214 of 245 cases of colorectal cancer, whereas no significant staining was observed in various normal tissues. We found elevated expression of EZH2 to be associated with poor prognosis for patients with NSCLC (P = 0.0239). In lung and bladder cancer cells overexpressing EZH2, suppression of EZH2 using specific siRNAs inhibited incorporation of BrdU and resulted in significant suppression of cell growth, even though no significant effect was observed in the normal cell strain CCD-18Co, which has undetectable EZH2. Because EZH2 expression was scarcely detectable in all normal tissues we examined, EZH2 shows promise as a tumor-specific therapeutic target. Furthermore, as elevated levels of EZH2 are associated with poor prognosis of patients with NSCLC, its overexpression in resected specimens could prove a useful molecular marker, indicating the necessity for a more extensive follow-up in some lung cancer patients after surgical treatment.
Collapse
Affiliation(s)
- Masashi Takawa
- Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Haga A, Sakumi A, Itoh S, Kon D, Kida S, Saotome N, Ohtomo K, Shiraishi K, Nakagawa K, Iwai Y. 1333 poster VMAT WITH MONACO, THE NOVEL TPS: PRESENT STATUS AND FUTURE APPLICATION. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71455-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Haga A, Kida S, Okano Y, Itoh S, Matsuura T, Saotome N, Sakumi A, Kotoku J, Kenshiro S, Nakagawa K, Iwai Y. SU-GG-T-135: Comparison of Treatment Planning Systems in Elekta Volumetric Modulated Arc Therapy (Elekta VMAT) - Prostate Cancer Study. Med Phys 2010. [DOI: 10.1118/1.3468525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Kawasaki S, Hara T, Iwai Y, Kanamori Y, Iwata A. Structural analyses of high-pressure and high-temperature treated double-walled carbon nanotubes. J Nanosci Nanotechnol 2010; 10:3994-3997. [PMID: 20355404 DOI: 10.1166/jnn.2010.1978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
This paper reports the structural properties of the high-pressure and high-temperature (HPHT) treated double-walled carbon nanotubes (DWCNTs) based on Raman, XRD and TEM experiments. It was found that the DWCNTs are more stable toward HPHT treatment than the single-walled carbon nanotubes (SWCNTs). We propose that this is probably because the DWCNTs tend not to be deformed by compression and thereby they are less reactive under pressure compared to SWCNTs.
Collapse
Affiliation(s)
- S Kawasaki
- Nagoya Institute of Technology, Gokiso, Showa, Nagoya 466-8555, Japan
| | | | | | | | | |
Collapse
|
43
|
Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, Ponder BAJ, Nakamura Y, Hamamoto R. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010; 9:59. [PMID: 20226085 PMCID: PMC2848192 DOI: 10.1186/1476-4598-9-59] [Citation(s) in RCA: 161] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Accepted: 03/13/2010] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Although an increasing number of histone demethylases have been identified and biochemically characterized, their biological functions largely remain uncharacterized, particularly in the context of human diseases such as cancer. We investigated the role of KDM5B, a JmjC histone demethylase, in human carcinogenesis. Quantitative RT-PCR and microarray analyses were used to examine the expression profiles of histone demethylases in clinical tissue samples. We also examined the functional effects of KDM5B on the growth of cancer cell lines treated with small interfering RNAs (siRNAs). Downstream genes and signal cascades induced by KDM5B expression were identified from Affymetrix Gene Chip experiments, and validated by real-time PCR and reporter assays. Cell cycle-dependent characteristics of KDM5B were identified by immunofluorescence and FACS. RESULTS Quantitative RT-PCR analysis confirmed that expression levels of KDM5B are significantly higher in human bladder cancer tissues than in their corresponding non-neoplastic bladder tissues (P < 0.0001). The expression profile analysis of clinical tissues also revealed up-regulation of KDM5B in various kinds of malignancies. Transfection of KDM5B-specific siRNA into various bladder and lung cancer cell lines significantly suppressed the proliferation of cancer cells and increased the number of cells in sub-G1 phase. Microarray expression analysis indicated that E2F1 and E2F2 are downstream genes in the KDM5B pathway. CONCLUSIONS Inhibition of KDM5B may affect apoptosis and reduce growth of cancer cells. Further studies will explore the pan-cancer therapeutic potential of KDM5B inhibition.
Collapse
Affiliation(s)
- Shinya Hayami
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
- Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan
| | - Masanori Yoshimatsu
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Abhimanyu Veerakumarasivam
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
- Medical Genetics Laboratory, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor Darul Ehsan, Malaysia
| | - Motoko Unoki
- Laboratory for Biomarker, RIKEN, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Yukiko Iwai
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Tatsuhiko Tsunoda
- Laboratory for Medical Informatics, RIKEN, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
| | - Helen I Field
- Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK
| | - John D Kelly
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
- Division of Surgery & Interventional Science, UCL Medical School, University College London, 74 Huntley Street, London, WC1E 6AU, UK
| | - David E Neal
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
| | - Hiroki Yamaue
- Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan
| | - Bruce AJ Ponder
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
| | - Yusuke Nakamura
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
| | - Ryuji Hamamoto
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
- Department of Oncology, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK
| |
Collapse
|
44
|
Soda S, Iwai Y, Sei K, Shimod Y, Ike M. Model analysis of energy consumption and greenhouse gas emissions of sewage sludge treatment systems with different processes and scales. Water Sci Technol 2010; 61:365-373. [PMID: 20107263 DOI: 10.2166/wst.2010.827] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
An energy consumption model was developed for evaluating sewage sludge treatment plants (SSTPs) incorporating various treatment processes such as thickening, anaerobic digestion, dewatering, incineration, and melting. Based on data analyses from SSTPs in Osaka, Japan, electricity consumption intensities for thickening, anaerobic digestion, dewatering, incineration, and melting and heat consumption intensities for anaerobic digestion, incineration, and melting were expressed as functions of sludge-loading on each unit process. The model was applied for predicting the energy consumption and greenhouse gas (GHG) emissions of SSTPs using various treatment processes and power and heat generation processes using digestion gas. Results showed that SSTPs lacking incineration and melting processes but having power generation processes showed excess energy production at the high sludge-loading rate. Energy consumption of the SSTPs without incineration and melting processes were low, but their GHG emissions were high because of CH(4) and N(2)O emissions from sludge cake at the landfill site. Incineration and melting processes consume much energy, but have lower CH(4) and N(2)O emissions.
Collapse
Affiliation(s)
- S Soda
- Division of Sustainable Energy and Environmental Engineering, Osaka University, Suita, Osaka, Japan. ,.ac.jp
| | | | | | | | | |
Collapse
|
45
|
Iwai Y, Nakatsuka M, Kumabe S. 238 THE FUNCTION OF TRPV4 EXPRESSION AND ITS NEURONAL ACTIVATION IN RESPONSE TO NOXIOUS STIMULATION OF ORAL MUCOSA. Eur J Pain 2009. [DOI: 10.1016/s1090-3801(09)60241-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Y. Iwai
- Department of Oral Anatomy, Osaka Denatl University, Hirakata, Japan
| | - M. Nakatsuka
- Department of Oral Anatomy, Osaka Denatl University, Hirakata, Japan
| | - S. Kumabe
- Department of Oral Anatomy, Osaka Denatl University, Hirakata, Japan
| |
Collapse
|
46
|
Yamanishi T, Hayashi T, Shu W, Kawamura Y, Nakamura H, Iwai Y, Kobayashi K, Isobe K, Arita T, Hoshi S, Suzuki T, Yamada M. Recent results of R&D activities on tritium technologies for ITER and fusion reactors at TPL of JAEA. Fusion Engineering and Design 2008. [DOI: 10.1016/j.fusengdes.2008.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Ikeda T, Kojima TM, Iwai Y, Kanai Y, Kambara T, Nebiki T, Narusawa T, Yamazaki Y. Production of a nm sized slow HCI beam with a guiding effect. ACTA ACUST UNITED AC 2007. [DOI: 10.1088/1742-6596/58/1/010] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
48
|
Morita E, Fukuda S, Nagano J, Hamajima N, Yamamoto H, Iwai Y, Nakashima T, Ohira H, Shirakawa T. Psychological effects of forest environments on healthy adults: Shinrin-yoku (forest-air bathing, walking) as a possible method of stress reduction. Public Health 2006; 121:54-63. [PMID: 17055544 DOI: 10.1016/j.puhe.2006.05.024] [Citation(s) in RCA: 195] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2005] [Revised: 04/18/2006] [Accepted: 05/17/2006] [Indexed: 02/08/2023]
Abstract
OBJECTIVES Shinrin-yoku (walking and/or staying in forests in order to promote health) is a major form of relaxation in Japan; however, its effects have yet to be completely clarified. The aims of this study were: (1) to evaluate the psychological effects of shinrin-yoku in a large number of participants; and (2) to identify the factors related to these effects. METHODS Four hundred and ninety-eight healthy volunteers took part in the study. Surveys were conducted twice in a forest on the same day (forest day) and twice on a control day. Outcome measures were evaluated using the Multiple Mood Scale-Short Form (hostility, depression, boredom, friendliness, wellbeing and liveliness) and the State-Trait Anxiety Inventory A-State Scale. Statistical analyses were conducted using analysis of variance and multiple regression analyses. RESULTS Hostility (P<0.001) and depression (P<0.001) scores decreased significantly, and liveliness (P=0.001) scores increased significantly on the forest day compared with the control day. The main effect of environment was also observed with all outcomes except for hostility, and the forest environment was advantageous. Stress levels were shown to be related to the magnitude of the shinrin-yoku effect; the higher the stress level, the greater the effect. CONCLUSIONS This study revealed that forest environments are advantageous with respect to acute emotions, especially among those experiencing chronic stress. Accordingly, shinrin-yoku may be employed as a stress reduction method, and forest environments can be viewed as therapeutic landscapes. Therefore, customary shinrin-yoku may help to decrease the risk of psychosocial stress-related diseases, and evaluation of the long-term effects of shinrin-yoku is warranted.
Collapse
Affiliation(s)
- E Morita
- Department of Health Promotion and Human Behaviour, Graduate School of Medicine, Kyoto University, Yoshida-Konoe, Sakyo-ku, Kyoto 606-8501, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Higashi H, Iwai Y, Miyazaki K, Arai Y. Molecular dynamics simulation of fluorination effect for solvation of trifluoromethylbenzoic acid isomers in supercritical carbon dioxide. Molecular Simulation 2005. [DOI: 10.1080/08927020500183299] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Yin L, Ohtaki H, Nakamachi T, Dohi K, Iwai Y, Funahashi H, Makino R, Shioda S. Expression of tumor necrosis factor alpha (TNFalpha) following transient cerebral ischemia. Acta Neurochir Suppl 2003; 86:93-6. [PMID: 14753413 DOI: 10.1007/978-3-7091-0651-8_21] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
It has been considered that tumor necrosis factor alpha (TNFalpha) is participated in the Alzheimer's, and Parkinson's diseases, brain injury and brain ischemia. However, expression of TNFalpha after brain ischemia has not been demonstrated in detail. Therefore we examined the cellular expression of TNFalpha during and after transient middle cerebral artery occlusion (tMCAO) in mice by use of reverse transcriptase-polymerase chain reaction and immunohistochemical technique. TNFalpha mRNA expression was gradually increased in the neocortex of the ipsilateral hemisphere during ischemia and peaked at 1 hour after reperfusion. Then, the mRNA expression decreased and peaked again at 24 hours after reperfusion. TNFalpha-like immunoreactivities were observed in the process such as dendrite of neuron slightly before ischemia, and markedly increased in neurons in addition to the process of the ipsilateral hemisphere at 1 and 24 hours after ischemia. The results suggest that the expression of TNFalpha is up-regulated in the neurons after tMCAO. TNFalpha may induce ischemic neuronal cell death during ischemic insult.
Collapse
Affiliation(s)
- L Yin
- Department of Anatomy, Showa University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|